A long-term observation and follow-up for patients with HBeAg/Anti-HBe seroconversion after lamivudine treatment.
- Author:
Jing-Li WU
1
;
Shao-Guang LI
;
Fan-Yuan WEN
;
Xiao-Yun YANG
;
Hua-Jian ZHOU
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antiviral Agents; therapeutic use; Female; Follow-Up Studies; Hepatitis B Antibodies; blood; Hepatitis B e Antigens; blood; Hepatitis B, Chronic; blood; drug therapy; Humans; Lamivudine; therapeutic use; Male
- From: Chinese Journal of Hepatology 2005;13(4):297-299
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the resulting change in patients who achieved HBeAg/Anti-HBe seroconversion after lamivudine treatment.
METHODS68 patients were observed for over 24 months. They were HBeAg/Anti-HBe with a seroconversion time > or = 6 months and the course of lamivudine treatment was > or = 18 months.
RESULTSAfter lamivudine treatment, the rate of HBeAg/Anti-HBe seroconversion was 25.19%, the rate of YMDD mutations was 20.59%, and the rate of relapse was 27.94% for these patients that achieved HBeAg/Anti-HBe seroconversion in observation and in the follow-up period. Lamivudine was still an effective drug for these patients with relapses. The rate of relapse was in correlation to the patients' age and the ALT level before treatment. The rate of relapse was not correlated to the HBV DNA level before the course of treatment. YMDD mutations were not correlated to the relapses.
CONCLUSIONEven with a HBeAg/Anti-HBe seroconversion time > or = 6 months, the rate of relapse was still higher in patients with chronic hepatitis B that received lamivudine. The patients with long-term lamivudine treatment should be observed and have frequent follow-up visits.
